COVID and Lung Cancer.
Curr Oncol Rep
; 23(11): 134, 2021 10 22.
Article
in English
| MEDLINE | ID: covidwho-1530397
ABSTRACT
PURPOSE OF REVIEW Since the past year, the fast spread of coronavirus disease 2019 (COVID-19) has represented a global health threat, especially for cancer patients, that has required an urgent reorganization of clinical activities. Here, we will critically revise the profound impact that the pandemic has generated in lung cancer patients, as well the most significant challenges that oncologists have to face to maintain the highest possible standards in the management of lung cancer patients in the pandemic era. RECENT FINDINGS:
Evidences suggested a higher susceptibility and mortality of lung cancer patients due to COVID-19. The hard management of this patient population has been also due to the potential cross interference of anti-tumor drugs on SARS-Cov-2 infection and to the differential diagnosis between COVID-19 pneumonitis and drug-related pneumonitis. COVID-19 pandemic has generated a profound reshaping of oncological activities and the development of recommendations by the oncology scientific community to prioritize anti-tumor treatments for lung cancer patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
COVID-19
/
Lung Neoplasms
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Oncol Rep
Journal subject:
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
S11912-021-01125-8
Similar
MEDLINE
...
LILACS
LIS